PolyPid (PYPD) Competitors $2.85 +0.23 (+8.78%) As of 04/30/2025 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYPD vs. LUCD, OBIO, AVR, INFU, KRMD, SKIN, MGRM, ICAD, NSPR, and MBOTShould you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Lucid Diagnostics (LUCD), Orchestra BioMed (OBIO), Anteris Technologies Global (AVR), InfuSystem (INFU), KORU Medical Systems (KRMD), Beauty Health (SKIN), Monogram Orthopaedics (MGRM), iCAD (ICAD), InspireMD (NSPR), and Microbot Medical (MBOT). These companies are all part of the "medical equipment" industry. PolyPid vs. Lucid Diagnostics Orchestra BioMed Anteris Technologies Global InfuSystem KORU Medical Systems Beauty Health Monogram Orthopaedics iCAD InspireMD Microbot Medical PolyPid (NASDAQ:PYPD) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Does the MarketBeat Community favor PYPD or LUCD? Lucid Diagnostics received 8 more outperform votes than PolyPid when rated by MarketBeat users. However, 80.00% of users gave PolyPid an outperform vote while only 68.97% of users gave Lucid Diagnostics an outperform vote. CompanyUnderperformOutperformPolyPidOutperform Votes3280.00% Underperform Votes820.00% Lucid DiagnosticsOutperform Votes4068.97% Underperform Votes1831.03% Which has preferable earnings and valuation, PYPD or LUCD? PolyPid has higher earnings, but lower revenue than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyPidN/AN/A-$29.02M-$4.97-0.57Lucid Diagnostics$4.35M30.31-$52.67M-$1.08-1.16 Which has more volatility & risk, PYPD or LUCD? PolyPid has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Do insiders & institutionals believe in PYPD or LUCD? 26.5% of PolyPid shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 8.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is PYPD or LUCD more profitable? PolyPid has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets PolyPidN/A -624.10% -129.28% Lucid Diagnostics -1,069.87%N/A -123.54% Do analysts prefer PYPD or LUCD? PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 297.66%. Lucid Diagnostics has a consensus price target of $3.50, suggesting a potential upside of 180.00%. Given PolyPid's stronger consensus rating and higher possible upside, research analysts plainly believe PolyPid is more favorable than Lucid Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media favor PYPD or LUCD? In the previous week, Lucid Diagnostics had 1 more articles in the media than PolyPid. MarketBeat recorded 5 mentions for Lucid Diagnostics and 4 mentions for PolyPid. Lucid Diagnostics' average media sentiment score of 0.46 beat PolyPid's score of 0.45 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryLucid Diagnostics beats PolyPid on 9 of the 17 factors compared between the two stocks. Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYPD vs. The Competition Export to ExcelMetricPolyPidSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.04M$4.39B$5.56B$7.82BDividend YieldN/A39.94%5.11%4.22%P/E Ratio-0.5730.6722.5118.48Price / SalesN/A54.91395.68103.60Price / CashN/A51.0838.1834.62Price / Book3.806.116.774.25Net Income-$29.02M$68.15M$3.22B$248.23M7 Day Performance7.14%-0.12%1.45%0.89%1 Month Performance7.75%-2.24%3.97%3.53%1 Year Performance-43.00%24.15%16.14%5.08% PolyPid Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYPDPolyPid2.1396 of 5 stars$2.85+8.8%$11.33+297.7%-40.3%$29.04MN/A-0.5780Upcoming EarningsShort Interest ↑News CoverageGap UpHigh Trading VolumeLUCDLucid Diagnostics2.5004 of 5 stars$1.20-0.8%$3.50+191.7%+38.7%$108.91M$4.35M-1.0570OBIOOrchestra BioMed2.7558 of 5 stars$2.84-0.4%$15.00+428.2%-32.7%$108.81M$2.64M-1.764Gap UpAVRAnteris Technologies GlobalN/A$3.14+9.0%$16.50+425.5%N/A$103.57M$2.71M0.00138News CoveragePositive NewsINFUInfuSystem1.4907 of 5 stars$4.91flat$13.00+164.8%-37.2%$103.19M$134.86M81.85410KRMDKORU Medical Systems3.2534 of 5 stars$2.24-1.3%$4.70+109.8%+26.7%$102.94M$33.65M-8.9680Upcoming EarningsNews CoverageSKINBeauty Health1.9939 of 5 stars$0.82-2.9%$2.50+204.4%-69.3%$102.86M$334.29M-1.961,030Upcoming EarningsNews CoverageMGRMMonogram Orthopaedics2.453 of 5 stars$2.65-1.9%$5.40+103.8%+47.7%$93.52M$364,999.00-5.6428Gap DownICADiCAD0.5748 of 5 stars$3.03-5.9%N/A+139.2%$82.92M$19.61M-23.31140Gap DownHigh Trading VolumeNSPRInspireMD2.5471 of 5 stars$2.60+0.4%$4.75+82.7%+30.9%$79.65M$7.01M-3.4750News CoveragePositive NewsGap UpMBOTMicrobot Medical1.8375 of 5 stars$2.23-10.4%$9.00+303.6%+165.6%$77.48MN/A-2.7920Gap Down Related Companies and Tools Related Companies Lucid Diagnostics Alternatives Orchestra BioMed Alternatives Anteris Technologies Global Alternatives InfuSystem Alternatives KORU Medical Systems Alternatives Beauty Health Alternatives Monogram Orthopaedics Alternatives iCAD Alternatives InspireMD Alternatives Microbot Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYPD) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PYPD Stock Free PYPD Stock Alerts